This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| transmissible spongiform encephalopathy | |
|---|---|
| Name | Transmissible spongiform encephalopathy |
| Field | Neurology, Infectious disease |
| Symptoms | Dementia, ataxia, myoclonus |
| Onset | Variable |
| Causes | Prions |
| Risks | Genetic mutations, exposure to infected tissue |
| Diagnosis | Clinical evaluation, EEG, MRI, CSF tests |
| Treatment | Supportive care |
| Frequency | Rare |
transmissible spongiform encephalopathy Transmissible spongiform encephalopathy is a group of progressive neurodegenerative disorders caused by misfolded prion proteins, presenting with rapidly progressive dementia, motor dysfunction, and fatal outcomes. First characterized through outbreaks and case series investigated by clinicians, researchers, and public health agencies, these diseases have been studied in the contexts of veterinary science, neurology, and molecular biology. High-profile investigations and policy responses involved institutions and figures across international medicine and agriculture.
TSEs were identified following observations in livestock and humans linked to distinct outbreaks and case reports involving Donald Rumsfeld-era agricultural controversies, Margaret Thatcher-era policy debates, and inquiries by commissions such as the Cullen Inquiry and Phillipps Commission that engaged Sir John Walton-era academic medicine and veterinary authorities. Early experimental work involved laboratories associated with University of Cambridge, University of Edinburgh, Wellcome Trust, and teams collaborating with the World Health Organization, Food and Agriculture Organization, and national agencies like the Department for Environment, Food and Rural Affairs and the Centers for Disease Control and Prevention. Landmark publications in journals edited by figures from Royal Society and institutions like National Institutes of Health shaped contemporary understanding, alongside case series reported in hospitals such as Mayo Clinic and Massachusetts General Hospital.
Clinical descriptions were refined by neurologists at centers including Johns Hopkins Hospital, University College London Hospitals, Charité – Universitätsmedizin Berlin, and Hôpital Pitié-Salpêtrière. Presentations commonly reported by clinicians in case reports from Royal Free Hospital, Addenbrooke's Hospital, Bellevue Hospital and field veterinarians at Roslin Institute include rapidly progressive cognitive decline, behavioral changes noted by psychiatrists at Maudsley Hospital, cerebellar ataxia observed by teams affiliated with Karolinska Institutet, and myoclonus documented in case series from Guy's Hospital and St Thomas' Hospital. Movement disorders described by investigators linked to National Hospital for Neurology and Neurosurgery and Hopkins clinics were corroborated by neuropathology findings from pathology departments at St Bartholomew's Hospital and Royal Victoria Infirmary.
Molecular studies led by laboratories at Rockefeller University, Scripps Research, Pasteur Institute, Max Planck Society and Cold Spring Harbor Laboratory elucidated that a normal host-encoded protein adopts a pathogenic conformation, underpinning theories advanced by researchers associated with Stanley B. Prusiner and collaborators at institutions such as University of California, San Francisco, Princeton University, and Yale University. Structural biologists at MRC Laboratory of Molecular Biology, ETH Zurich, and University of Oxford used techniques developed in part at European Molecular Biology Laboratory and Lawrence Berkeley National Laboratory to map conformational changes. Animal models generated at facilities like Roslin Institute and Wistar Institute and observed by teams from National Institute of Neurological Disorders and Stroke informed transmission studies conducted under guidelines from World Organisation for Animal Health and national research councils.
Epidemiologists and clinicians cataloged distinct entities observed in hospitals and research centers including Addenbrooke's Hospital and NIH: variant forms recognized in public health reports by Health Canada, Public Health England, and Centers for Disease Control and Prevention; sporadic forms described in case registries maintained at European Creutzfeldt-Jakob Disease Surveillance Network; familial forms associated with genetic counseling units at Mayo Clinic and Cleveland Clinic; and animal diseases tracked by veterinary services at USDA and DEFRA, including bovine cases investigated by research groups at University of Bristol and Royal Veterinary College. Specific diseases recorded in literature from institutions such as Imperial College London and University of Tokyo include human syndromes paralleling animal conditions observed in studies at INRAE and CSIC-affiliated labs.
Public health investigations led by agencies including World Health Organization, European Centre for Disease Prevention and Control, Centers for Disease Control and Prevention, Public Health England, and national ministries like Ministry of Health (Brazil), Ministry of Health and Family Welfare (India), and Health Ministry (Japan) traced transmission routes through iatrogenic exposures documented in hospital reports from Guy's Hospital and transfusion studies coordinated with blood services such as NHS Blood and Transplant and American Red Cross. Zoonotic concerns connected veterinary surveillance by OIE and agricultural policy decisions by European Commission and United States Department of Agriculture. Case registries curated by academic centers at University of Edinburgh and University of Toronto informed incidence estimates used by statisticians at Office for National Statistics and researchers affiliated with Johns Hopkins Bloomberg School of Public Health.
Diagnostic protocols developed by multidisciplinary teams from NIH, Mayo Clinic, Queen Square Centre for Neurological Disorders, and Karolinska University Hospital integrate clinical assessment with investigations including electroencephalography used in neurology wards at Massachusetts General Hospital, magnetic resonance imaging protocols refined at Stanford Health Care, cerebrospinal fluid assays implemented in laboratories at Viroclinics Biosciences and neuropathology confirmation in centers such as National Prion Clinic and pathology departments at UCLH and Hospital for Sick Children (Toronto). Surveillance networks like European CJD Surveillance Network and registries maintained by UK Health Security Agency standardize case definitions.
Clinical management guidelines issued by panels that included experts from World Health Organization, National Institute for Health and Care Excellence, American Academy of Neurology, and specialty societies from European Academy of Neurology emphasize palliative care coordinated through services at St Christopher's Hospice and symptom management regimens used in tertiary centers like Johns Hopkins Hospital and Mount Sinai Hospital. Experimental therapeutics trialed in academic consortia at Columbia University, Harvard Medical School, Massachusetts Institute of Technology, and biotech firms from Cambridge, Massachusetts and Silicon Valley focused on immunotherapy and antiprion compounds, with regulatory oversight by agencies such as Food and Drug Administration and European Medicines Agency.
Prevention strategies implemented by authorities including World Health Organization, Food and Agriculture Organization, World Organisation for Animal Health, and national bodies such as Defra and USDA encompassed feed bans, surveillance programs run by laboratories at APHA and CFIA, blood safety measures coordinated with NHS Blood and Transplant and American Red Cross, and policy responses informed by inquiries like the Cullen Inquiry and advisory panels convened by House of Commons committees and national ministries. International coordination through entities such as United Nations agencies and public health collaborations among universities including University of Edinburgh and Oxford University continues to guide risk reduction, animal health regulation, and clinical preparedness.